173 related articles for article (PubMed ID: 33806487)
21. Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer.
Di Fazio P; Waldegger P; Jabari S; Lingelbach S; Montalbano R; Ocker M; Slater EP; Bartsch DK; Illig R; Neureiter D; Wissniowski TT
Oncotarget; 2016 May; 7(20):28998-9010. PubMed ID: 27058414
[TBL] [Abstract][Full Text] [Related]
22. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
[TBL] [Abstract][Full Text] [Related]
23. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
Pettazzoni P; Pizzimenti S; Toaldo C; Sotomayor P; Tagliavacca L; Liu S; Wang D; Minelli R; Ellis L; Atadja P; Ciamporcero E; Dianzani MU; Barrera G; Pili R
Free Radic Biol Med; 2011 Jan; 50(2):313-22. PubMed ID: 21078383
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines.
Zopf S; Ocker M; Neureiter D; Alinger B; Gahr S; Neurath MF; Di Fazio P
BMC Cancer; 2012 Sep; 12():386. PubMed ID: 22943463
[TBL] [Abstract][Full Text] [Related]
25. Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma.
Liu L; Sun X; Xie Y; Zhuang Y; Yao R; Xu K
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29945926
[TBL] [Abstract][Full Text] [Related]
26. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
27. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
[TBL] [Abstract][Full Text] [Related]
28. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
29. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
30. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
[TBL] [Abstract][Full Text] [Related]
31. Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
Sanaei M; Kavoosi F
Asian Pac J Cancer Prev; 2021 Feb; 22(S1):89-95. PubMed ID: 33576217
[TBL] [Abstract][Full Text] [Related]
32. CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Chang Y; Lee YB; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
BMC Cancer; 2020 Oct; 20(1):1001. PubMed ID: 33059615
[TBL] [Abstract][Full Text] [Related]
33. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA
Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B
BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526
[TBL] [Abstract][Full Text] [Related]
35. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
36. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
37. A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma.
Espinoza AF; Patel RH; Patel KR; Badachhape AA; Whitlock R; Srivastava RK; Govindu SR; Duong A; Kona A; Kureti P; Armbruster B; Kats D; Srinivasan RR; Dobrolecki LE; Yu X; Najaf Panah MJ; Zorman B; Sarabia SF; Urbicain M; Major A; Bissig KD; Keller C; Lewis MT; Heczey A; Sumazin P; López-Terrada DH; Woodfield SE; Vasudevan SA
J Hepatol; 2024 Apr; 80(4):610-621. PubMed ID: 38242326
[TBL] [Abstract][Full Text] [Related]
38. Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells.
Wasim L; Chopra M
Biomed Pharmacother; 2016 Dec; 84():1393-1405. PubMed ID: 27802904
[TBL] [Abstract][Full Text] [Related]
39. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.
Liu YL; Yang PM; Shun CT; Wu MS; Weng JR; Chen CC
Autophagy; 2010 Nov; 6(8):1057-65. PubMed ID: 20962572
[TBL] [Abstract][Full Text] [Related]
40. Anti-metastatic potential of a proton beam is regulated by p38 MAPK/c-Fos signaling pathway in TPA-treated HepG2 human hepatocellular carcinoma.
Chun SY; Kim S; Nam KS; Lee KS
Biomed Pharmacother; 2018 Mar; 99():904-912. PubMed ID: 29710490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]